1. Home
  2. SLBT vs NVAX Comparison

SLBT vs NVAX Comparison

Compare SLBT & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SL Science Holding Limited Ordinary Shares

SLBT

SL Science Holding Limited Ordinary Shares

N/A

Current Price

$2.69

Market Cap

1.5B

Sector

N/A

ML Signal

N/A

Logo Novavax Inc.

NVAX

Novavax Inc.

HOLD

Current Price

$8.96

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLBT
NVAX
Founded
N/A
1987
Country
Taiwan
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.3B
IPO Year
2025
1996

Fundamental Metrics

Financial Performance
Metric
SLBT
NVAX
Price
$2.69
$8.96
Analyst Decision
Hold
Analyst Count
0
9
Target Price
N/A
$11.33
AVG Volume (30 Days)
72.2K
3.5M
Earning Date
N/A
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
309.76
EPS
N/A
N/A
Revenue
N/A
$1,123,479,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
64.69
52 Week Low
$2.54
$6.20
52 Week High
$6.25
$11.85

Technical Indicators

Market Signals
Indicator
SLBT
NVAX
Relative Strength Index (RSI) 40.10 64.09
Support Level $2.54 $8.42
Resistance Level $3.40 $10.10
Average True Range (ATR) 0.17 0.36
MACD 0.05 0.17
Stochastic Oscillator 0.00 91.14

Price Performance

Historical Comparison
SLBT
NVAX

About SLBT SL Science Holding Limited Ordinary Shares

SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

Share on Social Networks: